Second House Oversight Hearing Shines a Harsh Light on PBM Practices
Rena Conti, TPRI Faculty Director, quoted in Pharmacy Practice News, 09/19/23
Rena Conti, TPRI Faculty Director, quoted in Pharmacy Practice News, 09/19/23
Rena Conti, TPRI Faculty Director, quoted in NPR, July 27, 2023
Rena Conti, TPRI’s Faculty Director will lead the Opportunities for Biotechnology to Improve Pharmaceutical Supply Chain Resiliency pilot project (one of six pilot projects) in the National Network for Critical Technology Assessment.The project will systematically assess vulnerabilities in the supply chain of essential medicines and identify opportunities to improve supply chain resiliency. As part of […]
Rena Conti, TPRI Faculty Director, quoted in Medscape, May 26, 2023.
Rena Conti quoted in Bloomberg Law, January 31, 2023.
Rena Conti quoted in Axios, January 6, 2023.
Rena Conti’s OP-ED in Brookings Institution, November 7, 2022.
Rena Conti quoted in Reuters, February 8, 2023.
Insurers heavily subsidize the cost of ivermectin prescriptions for COVID, despite the lack of evidence that ivermectin is effective for COVID. In a new paper, published in JAMA, Questrom professor and TPRI co-lead Rena Conti with colleagues Kao-Ping Chua and Nora Becker (both University of Michigan) estimate that U.S. insurers may have wasted $2.5 million on these drugs in the week of August 13, 2021 alone.
TPRI faculty co-lead and Questrom faculty Rena Conti will testify at the upcoming U.S. House of Representatives hearing of the Committee on Oversight and Reform, entitled “Unsustainable Drug Prices: Findings from the Committee’s Drug Pricing Investigation and the Need for Structural Reforms.” on Friday, December 10, 2021, at 10 a.m. Professor Conti will discuss recently published papers germane to the current public debate on lowering prescription drug prices.